Revolution Medicines

Develops pills for hard-to-treat cancers like pancreatic cancer.

Company Health

/100

Fragile

A quick check of the business from its yearly reports (2025). It doesn’t say whether the stock is a good buy.

Does it make money?

0 of 25 · Poor

It doesn’t sell much yet, and it lost money last year.

Can it handle what it owes?

10 of 25 · Okay

Its business used cash last year, and it owes $31 of every $100 it owns.

Does it bring in spare cash?

0 of 25 · Poor

It spent more cash than it brought in last year.

Who owns it

2 of 23 own it · 1 bought more lately

bought lately

owns it

doesn’t own it

Didn’t report owning it: Whale Rock, Appaloosa, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre

Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners

From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Revolution Medicines’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales fell from $43.0 million in 2020 to $0 in 2025, and it lost money every year.

2025

Sales

Loss

$1.13 billion

Spare cash each year

It spent more cash than it brought in every year: $914 million more in 2025.

2025

Cash shortfall

$914 million

Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $2.35 billion, including $384 million in cash, and owed $723 million.

Key facts

From its yearly report for 2025.

Sales

Loss

$1.13 billion

Cash shortfall

$914 million

Cash in the bank

$384 million

Everything it owes

$723 million

Year ends

December

Money shown in

U.S. dollars

Latest yearly report

10-K, filed Feb 25, 2026

Figures from Revolution Medicines’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works